Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 15, 2005 - Issue 11
Submit an article Journal homepage
327
Views
40
CrossRef citations to date
0
Altmetric
Review

Sodium glucose co-transporter 2 (SGLT2) inhibitors as potential antidiabetic agents

Anthony L Handlon Metabolic and Viral Center of Excellence for Drug Discovery, GlaxoSmithKline, PO Box 13398, Research Triangle Park, North Carolina 27709-3398, USA
Pages 1531-1540 | Published online: 28 Oct 2005

Bibliography

  • EHRENKRANZ RRL, LEWIS NG, KAHN CR, ROTH J: Phlorizin:a review. Diabetes Metab. Res. Rev. (2005) 21:31–38.
  • ••Reviews SGLT inhibitors from a historicalperspective.
  • WELLS RG, PAJOR AM, KANAI Y et Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. Am. J. Physiol. (1992) 263:F459–F465.
  • KANAI Y, LEE W-S, YOU G, BROWN D,HEDIGER MA: The human kidney low affinity Na/glucose cotransporter SGLT2. Clin. Invest. (1994) 93:397–404.
  • •Expression and characterisation of the human renal glucose transporter.
  • WRIGHT EM, TURK E: The sodium/glucose cotransport family SLC5. Eur. j Physiol. (2004) 447:510–518.
  • ••Reviews the gene family to which SGLT2belongs.
  • WRIGHT EM: Renal Na-glucose cotransporters. Am. J. Physiol. Renal Physiol (2001) 280:F10–F18.
  • ZHOU L, CRYAN EV, D'ANDREA MR et al.: Human cardiomyocytes express high level of Na/glucose cotransporter 1 (SGLT1). J. Cell. Biochem. (2003) 90(2):339–346.
  • ELFEBER K, KOHLER A, LUTZENBURG M et al.: Localization of the Na*-D-glucose cotransporter SGLT1 in the blood-brain barrier. Histochem. Cell. Biol. (2004) 121(3):201–207.
  • DIEZ-SAMPEDRO A. HIRAYAMA BA, OSSWALD C et al.: A glucose sensor hiding in a family of transporters. Proc. Natl Acad. Sci. USA (2003) 100(20):11753–11758.
  • TAZAWA S, YAMATO T, FUJIKURA H et al.: SLC5A9/SGLT4, a new Na-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose. Lift Sci. (2005) 76:1039–1050.
  • KAISER N, LEIBOWITZ G, NESHER R: Glucotoxicity and 13-cell failure in Type 2 diabetes mellitus. J. Pediatric EndocrinoL Metab. (2003) 16(1):5–22.
  • MATHIS D, VENCE L, BENOIST C: 3-Cell death during progression to diabetes. Nature (2001) 414:792–798.
  • ••Reviews apoptotic 13-cell death in Type 1and Type 2 diabetes.
  • CERASI E, KAISER N, LEIBOWITZ G:Type 2 diabetes and 13-cell apoptosis. Diabetes Metab. (2000) 26:13–16.
  • SCHEEPERS A, JOOST H-G, SCHURMANN A: the glucose transporter families of SGLT and GLUT: molecular basis of normal and aberrant function. J. Parenteral Enteral Nutrition (2004) 28:365–371.
  • ASANO T, ANAI M, SAKODA H et al.: SGLT as a therapeutic target. Drugs Fut. (2004) 29:461–466.
  • •Recent review on the therapeutic potential of SGLTs.
  • ASANO T, OGIHARA T, KATAGIRI H et al.: Glucose transporter and Na/glucose cotransporter as molecular targets of anti-diabetic drugs. Curr. Med. Chem. (2004) 11:2717–2724.
  • OKU A, UETA K, ARAKAWA K et ell.: T-1095, an inhibitor of renal Na-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes (1999) 48:1794–1800.
  • •Landmark study on the pharmacology of SGLT2 inhibitors.
  • UETA K, ISHIHARA T, MATSUMOTO M et al: Long-term treatment with the Na-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kalcizaki rats. Life Sci. (2005) 76:2655–2668.
  • ••Recent results on the long-term treatmentwith an SGLT2 inhibitor.
  • CHANDRA J, ZHIVOTOVSKY B, ZAITSEV S et al.: Role of apoptosis in pancreatic B-cell death in diabetes. Diabetes (2001) 50:S44–S47.
  • MANDRUP-POULSEN T: B-cell apoptosis stimuli and signaling. Diabetes (2001) 50:S58–S63.
  • BUTLER AE, JANSON J, BONNER -WEIR S et al.: B-cell deficit and increased B-cell apoptosis in humans with Type 2 diabetes. Diabetes (2003) 52:102–110.
  • KAHN BB, FLIER JS: Obesity and insulinresistance. J. Clin. Invest. (2000) 106(4):473–481.
  • BONHOMME C: Posturination bladderresidue in the diabetic patient. Presse Medicale (1983) 12 (42): 2701.
  • GEERLINGS SE, STOLK RP, CAMPS MJL et al.: Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care (2000) 23(12):1737–1741.
  • ZIYADEH FN, SHARMA K: Overview: combating diabetic nephropathy. J. Am. Soc. Nephrol. (2003) 14:1355–1357.
  • SANTER R, KINNER M, LASSEN CL et al.: Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J. Am. Soc. Nephrol. (2003) 14:2873–2882.
  • http://www.diabetes.niddk.nih.gov/dm/pubs/ statistics/index.htm National Diabetes Information Clearinghouse (2005).
  • www.americanheart.org Metabolic Syndrome (2005).
  • http://en.sanofi-aventis.com Research/Metabolic Disorders (2005).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.